MedTrace Logo

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

NCT06566209 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.

Conditions

  • Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis
  • Myocarditis
  • ICI-Myocarditis
  • Solid Malignant Tumor
  • Hematologic Malignancy
  • Subclinical Myocarditis
  • Subclinical ICI-myocarditis

Interventions

DEVICE

Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)

Receive 18F-FDG PET/CT

Sponsors & Collaborators

Principal Investigators

  • Martin G. Rodriguez-Porcel, MD · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-11
Primary Completion
2025-12-22
Completion
2025-12-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06566209 on ClinicalTrials.gov